Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alfresa withdraws from AnGes dermatitis alliance

This article was originally published in Scrip

Executive Summary

Alfresa Pharma has decided to withdraw from a Japanese co-development agreement for a novel nucleic acid decoy therapy for atopic dermatitis. The company, part of the Alfresa pharmaceutical wholesaling group, had been developing the nuclear factor kappa-B decoy oligodeoxynucleotide product for this use with originator AnGes MG. Mixed Phase II data which showed benefits for certain topical doses were reported earlier this year (Scrip Online, February 20th, 2008). AnGes stressed that it was pressing ahead with plans for a Phase III trial and said that it would seek a new development partner.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel